DexCom DXCM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
DexCom (DXCM) Business Model and Operations Summary
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Key Insights
DexCom (DXCM) Core Market Data and Business Metrics
Latest Closing Price
$67.32Market Cap
$26.94 BillionPrice-Earnings Ratio
47.41Total Outstanding Shares
400.73 Million SharesTotal Employees
9,600Dividend
No dividendIPO Date
April 14, 2005SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
6340 Sequence Drive, San Diego, CA, 92121
Historical Stock Splits
If you bought 1 share of DXCM before June 13, 2022, you'd have 4 shares today.
| Execution Date | Split Amount |
|---|---|
| June 13, 2022 | 4-for-1 |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $989.50 Million |
| Net Cash Flow From Investing Activities, Continuing | $-207.50 Million |
| Net Cash Flow From Financing Activities | $-734.80 Million |
| Net Cash Flow, Continuing | $47.20 Million |
| Net Cash Flow From Financing Activities, Continuing | $-734.80 Million |
| Net Cash Flow From Operating Activities | $989.50 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Preferred Stock Dividends And Other Adjustments | $0 |
| Operating Income/Loss | $600 Million |
| Income Tax Expense/Benefit, Current | $176.60 Million |
| Revenues | $4.03 Billion |
| Cost Of Revenue | $1.59 Billion |
| Net Income/Loss | $576.20 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss Attributable To Parent | $8.70 Million |
| Comprehensive Income/Loss Attributable To Parent | $584.90 Million |
| Comprehensive Income/Loss | $584.90 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $584.90 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $2.18 Billion |
| Other Current Liabilities | $2.82 Billion |
| Equity | $2.10 Billion |
| Wages | $112 Million |
| Assets | $6.48 Billion |
| Liabilities And Equity | $6.48 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||